` BIVI (BioVie Inc) vs S&P 500 Comparison - Alpha Spread

BIVI
vs
S&P 500

Over the past 12 months, BIVI has underperformed S&P 500, delivering a return of -93% compared to the S&P 500's +14% growth.

Stocks Performance
BIVI vs S&P 500

Loading
BIVI
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BIVI vs S&P 500

Performance Gap Between BIVI and GSPC
HIDDEN
Show

Performance By Year
BIVI vs S&P 500

Loading
BIVI
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
BioVie Inc vs Peers

S&P 500
BIVI
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

BioVie Inc
Glance View

Market Cap
10.6m USD
Industry
Biotechnology

BioVie, Inc. is a biopharmaceutical company, which discovers, develops and commercializes drug therapies for liver disease. The company is headquartered in Santa Monica, California. The company went IPO on 2014-01-14. The firm is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The firm is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The firm is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.

BIVI Intrinsic Value
Not Available
Back to Top